# A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers

> **NCT06636877** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 52 (actual)

## Conditions studied

- Essential Hypertension
- Type 2 Diabetes

## Interventions

- **DRUG:** BR1019
- **DRUG:** BR1019-2
- **DRUG:** BR1019-3

## Key facts

- **NCT ID:** NCT06636877
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-23
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06636877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06636877, "A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06636877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*